Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.26355/eurrev_202005_21372 http://scihub22266oqcxt.onion/10.26355/eurrev_202005_21372 32495916!ä!32495916 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32495916&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Rev+Med+Pharmacol+Sci 2020 ; 24 (10): 5783-5787 Nephropedia Template TP {{tp|p=32495916|t=2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report |pdf=|usr=}}{{32495916}} gab.com Text Tocilizumab in the treatment of a critical COVID-19 patient: a case report JO: Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32495916 #FOAvip In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient. Twit Text FOAVip Tocilizumab in the treatment of a critical COVID-19 patient: a case report ????Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32495916 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32495916 #FOAvip English Wikipedia <ref>{{Cite pmid|32495916}}</ref> Tocilizumab in the treatment of a critical COVID-19 patient: a case report #MMPMID32495916 Wang L; Peng X; Wang ZH; Cai J; Zhou FC Eur Rev Med Pharmacol Sci 2020[May]; 24 (10): 5783-5787 PMID32495916show ga In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus/isolation & purification[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/pathology/virology[MESH] |Humans[MESH] |Leukocyte Count[MESH] |Lymphocyte Count[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology/virology[MESH] |Receptors, Interleukin-6/immunology[MESH] |SARS-CoV-2[MESH]Tocilizumab in the treatment of a critical COVID-19 patient: a case re(epmc).pdf DeepDyve Pubget Overpricing